(NVCR) Novocure - Ratings and Ratios
Electric Fields Device Cancer Care
NVCR EPS (Earnings per Share)
NVCR Revenue
Description: NVCR Novocure August 17, 2025
Novocure Ltd (NASDAQ:NVCR) is a Switzerland-originated healthcare equipment company with a market capitalization of $1.28 billion. The stock has been trending downward, with a current price of $11.73, significantly lower than its 52-week high of $33.41.
The companys financials indicate significant challenges, with a negative Return on Equity (RoE) of -47.74%, suggesting substantial losses. The forward Price-to-Earnings (P/E) ratio is extremely high at 909.09, implying that investors are pricing in significant future growth, which may be challenging given the current financial performance.
To evaluate the stocks potential, key economic drivers and KPIs to monitor include revenue growth, particularly from their flagship product, Tumor Treating Fields (TTFields) therapy; operating expense management; and cash burn rate. The companys ability to improve its gross margin and achieve profitability will be crucial. Additionally, the competitive landscape in the oncology treatment market, regulatory approvals, and reimbursement policies will significantly impact Novocures financial performance.
From a trading perspective, the stocks volatility, as measured by its Average True Range (ATR) of 0.58 (4.94%), and its beta of 0.608, indicate relatively lower volatility compared to the overall market. However, the stocks short-term and long-term moving averages (SMA20, SMA50, SMA200) suggest a bearish trend, with the stock price below all three averages, indicating potential further downside risk.
NVCR Stock Overview
| Market Cap in USD | 1,537m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2015-10-02 |
NVCR Stock Ratings
| Growth Rating | -82.8% |
| Fundamental | 32.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -39.3% |
| Analyst Rating | 4.14 of 5 |
NVCR Dividends
Currently no dividends paidNVCR Growth Ratios
| Growth Correlation 3m | 84.4% |
| Growth Correlation 12m | -77.3% |
| Growth Correlation 5y | -88% |
| CAGR 5y | -45.00% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.50 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.61 |
| Sharpe Ratio 12m | -0.94 |
| Alpha | -43.52 |
| Beta | 0.751 |
| Volatility | 66.87% |
| Current Volume | 1661.8k |
| Average Volume 20d | 1272.5k |
| Stop Loss | 11.4 (-6.8%) |
| Signal | -0.88 |
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (-170.9m TTM) > 0 and > 6% of Revenue (6% = 37.8m TTM) |
| FCFTA -0.06 (>2.0%) and ΔFCFTA 2.17pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 52.95% (prev 167.9%; Δ -115.0pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.04 (>3.0%) and CFO -44.7m > Net Income -170.9m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.45 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (111.6m) change vs 12m ago 3.59% (target <= -2.0% for YES) |
| Gross Margin 76.38% (prev 75.82%; Δ 0.56pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 51.27% (prev 45.37%; Δ 5.90pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -10.56 (EBITDA TTM -110.8m / Interest Expense TTM 11.7m) >= 6 (WARN >= 3) |
Altman Z'' -3.58
| (A) 0.27 = (Total Current Assets 1.08b - Total Current Liabilities 749.6m) / Total Assets 1.25b |
| (B) -0.99 = Retained Earnings (Balance) -1.23b / Total Assets 1.25b |
| (C) -0.10 = EBIT TTM -123.1m / Avg Total Assets 1.23b |
| (D) -1.38 = Book Value of Equity -1.23b / Total Liabilities 896.4m |
| Total Rating: -3.58 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 32.45
| 1. Piotroski 2.50pt = -2.50 |
| 2. FCF Yield -6.06% = -3.03 |
| 3. FCF Margin -12.76% = -4.78 |
| 4. Debt/Equity 2.00 = 0.77 |
| 5. Debt/Ebitda -4.97 = -2.50 |
| 6. ROIC - WACC (= -20.56)% = -12.50 |
| 7. RoE -47.74% = -2.50 |
| 8. Rev. Trend 90.52% = 6.79 |
| 9. EPS Trend 54.27% = 2.71 |
What is the price of NVCR shares?
Over the past week, the price has changed by -9.94%, over one month by -16.58%, over three months by +4.00% and over the past year by -26.28%.
Is Novocure a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NVCR is around 7.63 USD . This means that NVCR is currently overvalued and has a potential downside of -37.61%.
Is NVCR a buy, sell or hold?
- Strong Buy: 3
- Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the NVCR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 26.9 | 120.3% |
| Analysts Target Price | 26.9 | 120.3% |
| ValueRay Target Price | 8.4 | -31.6% |
NVCR Fundamental Data Overview October 26, 2025
P/E Forward = 909.0909
P/S = 2.4394
P/B = 4.4951
P/EG = -0.47
Beta = 0.751
Revenue TTM = 630.2m USD
EBIT TTM = -123.1m USD
EBITDA TTM = -110.8m USD
Long Term Debt = 97.6m USD (from longTermDebt, last quarter)
Short Term Debt = 559.8m USD (from shortTermDebt, last quarter)
Debt = 700.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 550.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.33b USD (1.54b + Debt 700.3m - CCE 911.5m)
Interest Coverage Ratio = -10.56 (Ebit TTM -123.1m / Interest Expense TTM 11.7m)
FCF Yield = -6.06% (FCF TTM -80.4m / Enterprise Value 1.33b)
FCF Margin = -12.76% (FCF TTM -80.4m / Revenue TTM 630.2m)
Net Margin = -27.13% (Net Income TTM -170.9m / Revenue TTM 630.2m)
Gross Margin = 76.38% ((Revenue TTM 630.2m - Cost of Revenue TTM 148.8m) / Revenue TTM)
Gross Margin QoQ = 73.88% (prev 75.15%)
Tobins Q-Ratio = 1.06 (Enterprise Value 1.33b / Total Assets 1.25b)
Interest Expense / Debt = 1.67% (Interest Expense 11.7m / Debt 700.3m)
Taxrate = -14.75% (negative due to tax credits) (5.16m / -35.0m)
NOPAT = -141.3m (EBIT -123.1m * (1 - -14.75%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 1.45 (Total Current Assets 1.08b / Total Current Liabilities 749.6m)
Debt / Equity = 2.00 (Debt 700.3m / totalStockholderEquity, last quarter 349.4m)
Debt / EBITDA = -4.97 (negative EBITDA) (Net Debt 550.6m / EBITDA -110.8m)
Debt / FCF = -6.85 (negative FCF - burning cash) (Net Debt 550.6m / FCF TTM -80.4m)
Total Stockholder Equity = 358.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -13.72% (Net Income -170.9m / Total Assets 1.25b)
RoE = -47.74% (Net Income TTM -170.9m / Total Stockholder Equity 358.1m)
RoCE = -27.01% (EBIT -123.1m / Capital Employed (Equity 358.1m + L.T.Debt 97.6m))
RoIC = -13.93% (negative operating profit) (NOPAT -141.3m / Invested Capital 1.01b)
WACC = 6.63% (E(1.54b)/V(2.24b) * Re(8.78%) + D(700.3m)/V(2.24b) * Rd(1.67%) * (1-Tc(-0.15)))
Discount Rate = 8.78% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.42%
Fair Price DCF = unknown (Cash Flow -80.4m)
EPS Correlation: 54.27 | EPS CAGR: 34.49% | SUE: 3.53 | # QB: 1
Revenue Correlation: 90.52 | Revenue CAGR: 7.25% | SUE: 0.81 | # QB: 0
Additional Sources for NVCR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle